Navamedic ASA: Annual Report 2024

30 Apr 2025 19:42 CEST

Oslo, April 30 2025 -  Navamedic ASA has today published its Annual Report for
2024. Find enclosed the report in PDF as well as an ESEF file version. The
report is also made available at the company's website at
https://navamedic.com/investors/annual-reports/

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail:
kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail:
lars.hjarrand@navamedic.com

About Navamedic:

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to
empower people to live healthier and more fulfilling lives. What sets us apart
is our deep-rooted commitment to understanding the needs and requirements of the
countries where we are present. Our local insight and competence enable us to
understand the specific needs of each country where we operate and ultimately to
gain market access. This makes us a preferred partner for international
companies expanding their footprint across the Nordics and Benelux regions,
through either in-licensing or out-licensing.

Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA)
and is headquartered in Oslo, Norway.

For more information, please visit Navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

645077_NavamedicASA_2024_12_31_0_en.zip
645077_Navamedic_Annual_Report_2024.pdf